O	0	10	Preventive
O	11	17	effect
O	18	20	of
B-intervention	21	25	oral
I-intervention	26	35	magnesium
O	36	38	in
B-condition	39	53	postmastectomy
I-condition	54	58	pain
O	58	59	:
O	60	68	protocol
O	69	72	for
O	73	74	a
O	75	85	randomised
O	85	86	,
O	87	93	double
O	93	94	-
O	94	99	blind
O	99	100	,
O	101	111	controlled
O	112	120	clinical
O	121	126	trial
O	126	127	.

O	128	134	Breast
O	135	141	cancer
O	142	149	affects
O	150	151	1
O	152	154	in
O	155	157	10
O	158	163	women
O	164	173	worldwide
O	173	174	,
O	175	178	and
O	179	189	mastectomy
O	190	192	is
O	193	194	a
O	195	200	cause
O	201	203	of
O	204	211	chronic
O	212	216	pain
O	217	221	with
O	222	233	neuropathic
O	234	249	characteristics
O	249	250	.

O	251	252	N
O	252	253	-
O	253	259	methyl
O	259	260	-
O	260	261	D
O	261	262	-
O	262	271	aspartate
O	272	280	receptor
O	281	282	(
O	282	287	NMDAR
O	287	288	)
O	289	300	antagonists
O	301	305	such
O	306	308	as
O	309	317	ketamine
O	317	318	,
O	319	328	memantine
O	328	329	,
O	330	346	dextromethorphan
O	347	349	or
O	350	359	magnesium
O	360	363	are
O	364	368	used
O	369	371	to
O	372	377	treat
O	378	388	refractory
O	389	393	pain
O	394	396	by
O	397	405	blocking
O	406	411	NMDAR
O	411	412	.

O	413	417	Oral
O	418	427	memantine
O	428	431	has
O	432	436	been
O	437	442	shown
O	443	445	to
O	446	453	prevent
O	454	468	postmastectomy
O	469	473	pain
O	474	477	and
O	478	487	cognitive
O	488	494	impact
O	495	498	and
O	499	501	to
O	502	510	maintain
O	511	518	quality
O	519	521	of
O	522	526	life
O	526	527	.

O	528	536	Likewise
O	536	537	,
O	538	541	the
O	542	549	present
O	550	555	study
O	556	558	is
O	559	567	intended
O	568	570	to
O	571	577	assess
O	578	581	the
O	582	592	preventive
O	593	599	effect
O	600	602	of
O	603	607	oral
O	608	617	magnesium
O	617	618	,
O	619	631	administered
O	632	637	ahead
O	638	640	of
O	641	651	mastectomy
O	651	652	,
O	653	655	on
O	656	659	the
O	660	671	development
O	672	674	of
O	675	686	neuropathic
O	687	691	pain
O	691	692	.

O	693	695	As
O	696	697	a
O	698	711	physiological
O	712	719	blocker
O	720	722	of
O	723	728	NMDAR
O	728	729	,
O	730	739	magnesium
O	740	745	could
O	746	748	be
O	749	751	an
O	752	763	interesting
O	764	773	candidate
O	774	776	to
O	777	784	prevent
O	785	798	postoperative
O	799	803	pain
O	804	807	and
O	808	818	associated
O	819	832	comorbidities
O	832	833	,
O	834	843	including
O	844	853	cognitive
O	854	857	and
O	858	867	emotional
O	868	877	disorders
O	877	878	,
O	879	887	multiple
O	888	897	analgesic
O	898	909	consumption
O	910	913	and
O	914	922	impaired
O	923	930	quality
O	931	933	of
O	934	938	life
O	938	939	.

O	940	941	A
O	942	952	randomised
O	953	959	double
O	959	960	-
O	960	965	blind
O	966	976	controlled
O	977	985	clinical
O	986	991	trial
O	992	993	(
O	993	1004	NCT03063931
O	1004	1005	)
O	1006	1010	will
O	1011	1018	include
B-total-participants	1019	1022	100
B-eligibility	1023	1028	women
I-eligibility	1029	1033	with
I-eligibility	1034	1040	breast
I-eligibility	1041	1047	cancer
I-eligibility	1048	1058	undergoing
I-eligibility	1059	1069	mastectomy
O	1070	1072	at
O	1073	1076	the
O	1077	1085	Oncology
O	1086	1094	Hospital
O	1094	1095	,
O	1096	1104	Clermont
O	1104	1105	-
O	1105	1112	Ferrand
O	1112	1113	,
B-location	1114	1120	France
O	1120	1121	.

O	1122	1131	Magnesium
O	1132	1133	(
O	1133	1136	100
O	1137	1139	mg
O	1139	1140	/
O	1140	1143	day
O	1143	1144	;
O	1145	1146	n
O	1146	1147	=
B-intervention-participants	1147	1149	50
O	1149	1150	)
O	1151	1153	or
B-control	1154	1161	placebo
O	1162	1163	(
O	1163	1164	n
O	1164	1165	=
B-control-participants	1165	1167	50
O	1167	1168	)
O	1169	1173	will
O	1174	1176	be
O	1177	1189	administered
O	1190	1193	for
O	1194	1195	6
O	1196	1201	weeks
O	1201	1202	,
O	1203	1211	starting
O	1212	1213	2
O	1214	1219	weeks
O	1220	1226	before
O	1227	1234	surgery
O	1234	1235	.

O	1236	1245	Intensity
O	1246	1248	of
O	1249	1253	pain
O	1253	1254	,
O	1255	1264	cognitive
O	1265	1268	and
O	1269	1278	emotional
O	1279	1287	function
O	1288	1291	and
O	1292	1299	quality
O	1300	1302	of
O	1303	1307	life
O	1308	1312	will
O	1313	1315	be
O	1316	1324	assessed
O	1325	1327	by
O	1328	1342	questionnaires
O	1342	1343	.

O	1344	1347	The
O	1348	1355	primary
O	1356	1364	endpoint
O	1365	1367	is
B-outcome-Measure	1368	1372	pain
I-outcome-Measure	1373	1382	intensity
I-outcome-Measure	1383	1385	on
I-outcome-Measure	1386	1387	a
I-outcome-Measure	1388	1389	0
I-outcome-Measure	1389	1390	-
I-outcome-Measure	1390	1392	10
I-outcome-Measure	1393	1402	numerical
I-outcome-Measure	1403	1409	rating
I-outcome-Measure	1410	1415	scale
I-outcome-Measure	1416	1418	at
I-outcome-Measure	1419	1420	1
I-outcome-Measure	1421	1426	month
I-outcome-Measure	1427	1441	postmastectomy
I-outcome-Measure	1441	1442	.

O	1443	1447	Data
O	1448	1456	analysis
O	1457	1461	will
O	1462	1465	use
O	1466	1471	mixed
O	1472	1478	models
O	1478	1479	;
O	1480	1483	all
O	1484	1489	tests
O	1490	1494	will
O	1495	1497	be
O	1498	1501	two
O	1501	1502	-
O	1502	1508	tailed
O	1508	1509	,
O	1510	1514	with
O	1515	1519	type
O	1519	1520	-
O	1520	1521	I
O	1522	1527	error
O	1528	1531	set
O	1532	1534	at
O	1535	1536	Î±
O	1536	1537	=
O	1537	1538	0
O	1538	1539	.
O	1539	1541	05
O	1541	1542	.

O	1543	1546	The
O	1547	1552	study
O	1553	1561	protocol
O	1562	1565	and
O	1566	1574	informed
O	1575	1582	consent
O	1583	1587	form
O	1588	1592	were
O	1593	1601	approved
O	1602	1604	in
O	1605	1613	December
O	1614	1618	2016
O	1619	1621	by
O	1622	1625	the
O	1626	1632	French
O	1633	1641	Research
O	1642	1648	Ethics
O	1649	1658	Committee
O	1659	1660	(
O	1660	1665	South
O	1666	1670	East
O	1671	1673	VI
O	1674	1683	Committee
O	1683	1684	)
O	1684	1685	.

O	1686	1693	Results
O	1694	1698	will
O	1699	1701	be
O	1702	1714	communicated
O	1715	1717	in
O	1718	1725	various
O	1726	1736	congresses
O	1737	1740	and
O	1741	1750	published
O	1751	1753	in
O	1754	1767	international
O	1768	1780	publications
O	1780	1781	.

O	1782	1793	NCT03063931
O	1793	1794	.
